Insys stock: buy or sell?

INSY stock price: $65,799,000.00 25.00% At close on June 28th, 2019

Updated on:
June 28th, 2019

4

Insys crossed up the SMA line of 200 days today and closed at $65,799,000.00. On Jun 20th INSY plummed a bloodcurdling -11.54%. Last session broke a streak of 4 red sessions in a row.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States.

Should I buy Insys stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Having a trading plan helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Currently, Insys stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean INSY will fall in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Insys stock a buy?

Banks and financial institutions publish stock ratings everyday. At Stocks2.com, we collected 2 ratings published for INSY stock in the last 30 days.

Is INSY a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-3-8Royal Bank of CanadaOutperformOutperform
2019-1-22Cantor Fitzgeraldn/aOverweight

Insys stock analysis

Daily outlook

After sliding for 4 days, June 28th Insys Therapeutics rocketed an extraordinary 25,307,307,592.31%, closing at $65,799,000.00.

Insys shares broke up the simple moving average line of 200 days today and closed at $65,799,000.00. On June 28th, SMA100d and SMA200d crossed up triggering a rise of 25,307,307,592.31%. INSY broke out again over $0.74 after a 72.97% correction started on Jun 12th.

INSY stock chart (daily)

Weekly outlook

After sliding a chilling -30.77% in a week by mid June, Insys closed this week at $65,799,000.00 and rocketed a super good 25,307,307,592.31%.

Late June, SMA20w and SMA40w crossed up triggering a rise of 25,307,307,592.31%. Since price and SMA40w lines crossed up late June, INSY climbed $65,798,999.74 (25,307,307,592.31%).

INSY stock chart (weekly)

Insys stock price history

Insys IPO was on November 2nd, 2017 at $4.79 per share1. Since then, INSY stock grew a 1,373,674,221.50%, with an average of 1,373,674,221.50% per year. If you had invested right after INSY's IPO a $1,000 in Insys stock in 2017, it would worth $13,736,742,215.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Insys stock historical price chart

INSY stock reached 52-week highs on August at $11.65, and all-time highs 2018-01-03 with a price of 14.

Insys stock price target is $7.00

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' INSY stock price predictions in the hope that they will be met as they may be wrong and not met. Currently, only 1 price prediction for Insys Therapeutics stock was posted in the last 30 days:
INSY stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-3-8Royal Bank of CanadaLowers Target$9.00$7.00-22.2%
(in average)$9.00$7.00-22.0%

Financials and fundamental analysis

Earnings date and Earnings per Share

Insys presented cool results for 2018-Q4 on March. Insys Therapeutics soared Earnings per Share (EPS) by 18.20%, beating experts of $-0.33. Insys Therapeutics posted $-0.39.
INSY earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.09n/a
2017-Q2-n/a-0.07n/a
2017-Q32017-11-02-0.16-0.21n/a
2017-Q42018-03-08n/a-0.23n/a
2018-Q12018-05-08-0.24-0.22n/a
2018-Q22018-08-08-0.25-0.37n/a
2018-Q32018-11-05-0.32-0.4n/a
2018-Q42019-03-07-0.33-0.39n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

In 2018, Insys annual revenues plummed a scary -41.66% to $82.08 M USD from $140.69 marked in 2017. When comparing 2018 vs 2017, by contrast, profit margin (that is, the net income divided by revenues) jumped a 9.54% to -151.69%.

INSY annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$99 M-$40 M40.7%-
2014$222 M123.71%$38 M17.1%-5.95%
2015$331 M48.92%$58 M17.7%53.98%
2016$242 M-26.76%$7.59 M3.1%-87.02%
2017$141 M-41.93%$-226.84 M-161.2%-3,088.60%
2018$82 M-41.66%$-124.51 M-151.7%-45.11%

Quarterly financial results

Insys reported $16.36 million in revenues for 2018-Q4, a -10.84% decline compared to previous quarter. Reported quarter income marked $-46.29 million with a profit margin of -283.02%. Profit margin plunged a -116.80% compared to previous quarter when profit margin was -166.22%. When comparing sales to same quarter last year, Insys Therapeutics sales marked a frightening correction and plummed a -48.05%. Looking back to recent quarterly results, Insys posted 4 positive quarters in a row.
INSY quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q1$36 M-$-6.52 M-18.1%-
2017-Q2$43 M18.41%$-8.18 M-19.2%25.46%
2017-Q3$31 M-27.97%$-166.32 M-542.3%1,933.25%
2017-Q4$31 M2.66%$-47.11 M-149.6%-71.68%
2018-Q1$24 M-24.06%$-20.37 M-85.2%-56.76%
2018-Q2$23 M-1.86%$-27.35 M-116.6%34.27%
2018-Q3$18 M-21.82%$-30.49 M-166.2%11.50%
2018-Q4$16 M-10.84%$-46.29 M-283.0%51.81%

Insys ownership

When you are planning to buy shares of a company, it's always worth to check its ownership structure.

Insys Therapeutics shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a of all shares.

The following table compares ownership indicators for other stocks related to Insys Therapeutics:

INSYACRXBDSIGWPHHRTX
Market cap$0.0 M$218.6 M$218.5 M$5.2 B$1.4 B
Total shares0.0 M78.9 M55.9 M30.7 M79.2 M
Float shares0.0 M77.9 M71.8 M29.8 M66.0 M
  - Institutional holdings (%)0.0%19.7%58.8%82.0%117.6%
  - Insider holdings (%)0.0%11.6%6.0%0.6%0.1%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

Insys summary

Friday, June 28th, 2019
Open$0.27
Close$65799000.00
Day range$0.25 - $0.38
Previous close$0.26
Session gain25,307,307,592.31%
Average true range$0.31
50d mov avg$1,315,980.00
100d mov avg$657,994.00
200d mov avg$329,000.00
Daily patternlb01c
Weekly pattern lb06c

Insys performance

To better understand Insys performance you must compare its gains with other related stocks in same sector or industry. We compared Insys against AcelRx Pharmaceuticals, BioDelivery Sciences International, GW Pharmaceuticals, Heron Therapeutics, Merck, Mylan and Recro Pharma in the following table:
Stock3m6m12m
INSYInsys Therapeutic...1424220000.00%1896220000.00%908826000.00%
ACRXAcelRx Pharmaceut...-18.29%6.13%-13.44%
BDSIBioDelivery Scien...-15.91%-9.49%39.64%
GWPHGW Pharmaceutical...7.56%22.12%14.66%
HRTXHeron Therapeutic...-22.17%-32.33%-53.10%
MRKMerck11.35%8.14%33.05%
MYLMylan-29.35%-35.89%-46.61%
REPHRecro Pharma19.95%28.39%81.88%

Insys competitors

One check before trading any stock is to review a list of its competitors, in this case for Insys. We chose 7 companies as Insys competitors as they are in the same industry or have similar market objectives.